SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients – A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease

SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients – A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease

BackgroundIndividuals with secondary immunodeficiencies belong to the most vulnerable groups to succumb to COVID-19 and thus are prioritized for SARS-CoV-2 vaccination. However, knowledge about the persistence and anamnestic responses following SARS-CoV-2-mRNA vaccinations is limited in these patien...

Full description

Bibliographic Details
Main Authors: Angelika Wagner, Erika Garner-Spitzer, Anna-Margarita Schötta, Maria Orola, Andrea Wessely, Ines Zwazl, Anna Ohradanova-Repic, Lukas Weseslindtner, Gabor Tajti, Laura Gebetsberger, Bernhard Kratzer, Elena Tomosel, Maximilian Kutschera, Selma Tobudic, Winfried F. Pickl, Michael Kundi, Hannes Stockinger, Gottfried Novacek, Walter Reinisch, Christoph Zielinski, Ursula Wiedermann
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Immunology
Subjects:
patients under immunosuppression/immunomodulation
SARS-CoV-2 mRNA vaccination
booster vaccination
humoral and cellular vaccine-specific responses
antibody testing
waning of immune responses
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.889138/full

Similar Items

Similar Items